Pharmaceutical News

RSS

Wellstat Therapeutics and Sanofi-Aventis to develop, manufacture and commercialize PN2034

Wellstat Therapeutics Corporation and sanofi-aventis announced today a global licensing agreement to develop, manufacture and commercialize PN2034, a first-in-class oral insulin sensitizer for the treatment of Type II diabetes.

21 Oct 2009

Logical Therapeutics to present its clinical study results on LT-NS001

Logical Therapeutics, Inc. (Logical), a biopharmaceutical company focused on developing products that treat medical conditions associated with inflammation, has been selected to present the results of its clinical study comparing the gastrointestinal (GI) safety of its lead product LT-NS001, vs. naproxen at the American College of Gastroenterology's (ACG) Annual Scientific Meeting on October 27, 2009.

21 Oct 2009

CHA urges California Nurses Association to promote vaccinations to all health care workers

The California Hospital Association (CHA) is engaged with hospitals and state and local public health officials in a voluntary statewide effort to ensure that all hospital workers -- including registered nurses -- are vaccinated against the H1N1 flu virus.

21 Oct 2009

Novo Nordisk's Levemir not associated with increase in the incidence of cancer

A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes (EASD), demonstrated that the Novo Nordisk long-acting insulin Levemir® (insulin detemir [rDNA origin] injection) was not associated with any increase in the incidence of cancer when compared to human insulin.

From Novo Nordisk 21 Oct 2009

Osteologix to continue clinical development of NB S101 osteoporosis drug

Osteologix, Inc., a bio-pharmaceutical company announced today that the company will continue the clinical development for its osteoporosis drug, NB S101 (strontium malonate), in the United States and the rest of the world markets. Additionally, the company wants to recognize World Osteoporosis Day’s significance and make more people aware of its research dedicated to improving the lives of people with osteoporosis.

21 Oct 2009

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

Simcere Pharmaceutical Group ("Simcere" or the "Company"), a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement with OSI Pharmaceuticals, Inc., to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China.

21 Oct 2009

Inovio Biomedical highlights its advances in SynCon DNA vaccines

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced that Dr. David B. Weiner, Chairman of Inovio’s Scientific Advisory Board, highlighted advances in electroporation-delivered SynCon™ DNA vaccines compared to other leading vaccine technologies at the AIDS Vaccine 2009 Conference being held this week in Paris, France.

21 Oct 2009

As HIV vaccine conference opens, experts appeal for sustained commitment to global fight against disease

Experts, gathered for the start of a four-day conference on HIV vaccines in Paris, called upon donors to maintain their funding support for the fight against HIV/AIDS despite the global economy, Agence France-Presse reports.

20 Oct 2009

ImPACKD calls for raising awareness about the risks of calcium overuse in CKD patients

Most Canadians living with CKD have likely never spoken with their physicians about calcium and the serious health risks associated with its overuse. This is why Improving Patient Advocacy in Chronic Kidney Disease (ImPACKD), a group of CKD patients and caregivers committed to raising awareness about the risks of calcium overuse, is starting the conversation about the importance of knowing the limits and keeping them in check.

20 Oct 2009

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

Merck Frosst Canada Ltd. is pleased to announce that (Pr)ISENTRESS(R) (raltegravir) is now indicated for use in treatment-naïve HIV-1 infected adults in combination with other antiretroviral agents.

20 Oct 2009

Boehringer Ingelheim continues providing non assert declarations to manufacture HIV/AIDS medicines

Boehringer Ingelheim continues to be willing to provide WHO qualified generic pharmaceutical companies non assert declarations to manufacturer and export products containing the HIV/AIDS medication nevirapine to Rwanda and other defined developing countries.

20 Oct 2009

TechnoVax receives NIH grant to further the development of its VLP-based, vaccine program

TechnoVax, Inc., a biotechnology developer of novel vaccines was awarded a three-year $2.9 million SBIR phase II grant from the National Institutes of Health to further the development of its VLP-based, vaccine program.

20 Oct 2009

Meeting to discuss latest information on anti-aging medicine and euthanasia

America's foremost authorities on aging will share the latest information on "death panels," anti-aging medicine, health care reform, and other current topics at The Gerontological Society of America's upcoming 62nd Annual Scientific Meeting. This four day event - the country's largest interdisciplinary conference in the field of aging - will take place from November 18 to 22 in Atlanta, GA. Media representatives can register free of charge.

20 Oct 2009

GlaxoSmithKline to allow Apotex continue manufacturing their drug in Rwanda

GlaxoSmithKline Inc. (GSK) As part of its broad commitment to improving access to medicines and its ongoing support for Canada's Access to Medicines Regime (CAMR), GlaxoSmithKline confirms it will not object - through CAMR - to allow Canadian company (Apotex) to continue manufacturing their drug for the treatment of HIV/AIDS in Rwanda.

20 Oct 2009

USP offers redesigned pharmaceutical standards format to improve key documentation process

To improve key documentation relied upon by the pharmaceutical industry and others, the U.S. Pharmacopeial (USP) Convention announces the release of the redesigned United States Pharmacopeia-National Formulary (USP-NF).

20 Oct 2009

PCV vaccines can save the lives of millions of children

A study published in The Cochrane Review this month concludes that pneumococcal conjugate vaccines (PCV), already known to prevent invasive pneumococcal disease (IPD) and x-ray defined pneumonia, was also effective against child deaths.

20 Oct 2009

AHF reiterates its disappointment over the presentation of Thai HIV vaccine study data

In anticipation of today’s controversial presentation of the Thai HIV vaccine study data at the AIDS Vaccine Conference in Paris, AIDS Healthcare Foundation (AHF) reiterated its disappointment at the news that data that seriously undermined the purported success of the trial were not released publicly when other, more favorable data were reported late last month.

20 Oct 2009

Pharmacy services still in demand despite recession

Despite the onset of an economic recession during 2008, pharmacy services were still in demand due to their value in the health care delivery system. The average community pharmacy saw its total sales increase by 7.6% to $3.9 million.

20 Oct 2009

Two high blood pressure medicines effective in treating stable ischemic heart disease

Two medications commonly used to treat high blood pressure appear to be effective in treating a common type of heart disease known as stable ischemic heart disease, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

20 Oct 2009

Novavax, Avimex and GE Healthcare initiate clinical study of H1N1 VLP influenza vaccine

Novavax, Inc. (Nasdaq: NVAX) announced today that it has initiated a two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare.

20 Oct 2009

Pharmaceutical News

Wellstat Therapeutics and Sanofi-Aventis to develop, manufacture and commercialize PN2034

Logical Therapeutics to present its clinical study results on LT-NS001

CHA urges California Nurses Association to promote vaccinations to all health care workers

Novo Nordisk's Levemir not associated with increase in the incidence of cancer

Osteologix to continue clinical development of NB S101 osteoporosis drug

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

Inovio Biomedical highlights its advances in SynCon DNA vaccines

As HIV vaccine conference opens, experts appeal for sustained commitment to global fight against disease

ImPACKD calls for raising awareness about the risks of calcium overuse in CKD patients

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

Boehringer Ingelheim continues providing non assert declarations to manufacture HIV/AIDS medicines

TechnoVax receives NIH grant to further the development of its VLP-based, vaccine program

Meeting to discuss latest information on anti-aging medicine and euthanasia

GlaxoSmithKline to allow Apotex continue manufacturing their drug in Rwanda

USP offers redesigned pharmaceutical standards format to improve key documentation process

PCV vaccines can save the lives of millions of children

AHF reiterates its disappointment over the presentation of Thai HIV vaccine study data

Pharmacy services still in demand despite recession

Two high blood pressure medicines effective in treating stable ischemic heart disease

Novavax, Avimex and GE Healthcare initiate clinical study of H1N1 VLP influenza vaccine

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Latest News